Pharmacogenetic determinants of anti-cancer drug activity and toxicity

被引：44

作者：

Danesi, R

De Braud, F

Fogli, S

Di Paolo, A

Del Tacca, M

机构：

[1] Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Div Pharmacol & Chemotherapy, I-56126 Pisa, Italy

[2] European Inst Oncol, Div Med Oncol, Clin Pharmacol & New Drug Dev Unit, I-20142 Milan, Italy

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2001年 / 22卷 / 08期

关键词：

D O I：

10.1016/S0165-6147(00)01742-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets and mechanisms of damage repair. Despite the pharmacological advances in the treatment of cancer, the clinical efficacy of chemotherapy is unpredictable in most patients. However, new information on the genetics of cancer delineates strategies by which the genetic background of tumour cells and patients might be profiled to select anti-cancer agents with improved efficacy and tolerability. This article focuses on the application of pharmacogenetics in the characterization of differences in the pharmacokinetics and pharmacodynamics of anti-cancer agents among individuals to define the likelihood of response and reduce the incidence of adverse effects.

引用

页码：420 / 426

页数：7

共 54 条

[11] Pharmacogenomics: Translating functional genomics into rational therapeutics [J].

Evans, WE ;

Relling, MV .

SCIENCE, 1999, 286 (5439) :487-491

[12] Association of CYP3A4 genotype with treatment-related leukemia [J].

Felix, CA ;

Walker, AH ;

Lange, BJ ;

Williams, TM ;

Winick, NJ ;

Cheung, NKV ;

Lovett, BD ;

Nowell, PC ;

Blair, IA ;

Rebbeck, TR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181

[13] p16(INK4) expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors [J].

Fukuoka, K ;

Adachi, J ;

Nishio, K ;

Arioka, H ;

Kurokawa, H ;

Fukumoto, H ;

Ishida, T ;

Nomoto, T ;

Yokote, H ;

Tomonari, A ;

Narita, N ;

Yokota, J ;

Saijo, N .

JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (10) :1009-1016

[14] Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer:: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage [J].

Gamelin, E ;

Boissdron-Celle, M ;

Guérin-Meyer, V ;

Delva, R ;

Lortholary, A ;

Genevieve, F ;

Larra, F ;

Ifrah, N ;

Robert, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1105-1110

[15]

Gazitt Y, 1998, INT J ONCOL, V13, P839

[16]

Goan YG, 1999, CANCER RES, V59, P4204

[17]

Green SL, 1998, CANCER J SCI AM, V4, P218

[18]

GROMPE M, 1998, PRINCIPLES MOL MED, P9

[19]

Holden JA, 1997, ANN CLIN LAB SCI, V27, P402

[20] Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer [J].

Holmqvist, P ;

Lundström, M ;

Stål, O .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (02) :84-91

← 1 2 3 4 5 6 →